Immunosuppressive mechanisms in cancer: Consequences for the development of therapeutic vaccines

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3398-3400

  Gross, Stefanie ^a   Geldmacher, Astrid ^a   Sharav, Tumenjargal ^a   Losch, Florian ^a   Walden, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer; Clinical trial; Immunosuppression; Immunotherapy; Melanoma; Mimotope; T cell; T cell epitope; T cell directed vaccine; Therapeutic vaccination; Therapeutic vaccine; Tumor immunology

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; MELANOMA VACCINE; PROLYLVALYLLYSYLTHREONYLLYSYLASPARTYLISOLEUCYLLYSYLLEUCINE VACCINE; PROLYLVALYLLYSYLTHREONYLTYROSYLASPARTYLISOLEUCYLLYSYLLEUCINE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL STIMULATION; CLINICAL TRIAL; CLONAL ANERGY; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; MELANOMA; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNE TOLERANCE; NEOPLASMS; T-LYMPHOCYTES;

EID: 67349264097     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.070     Document Type: Article

References (12)

1. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
2. Novellino L., Castelli C., and Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54 (2005) 187-207
3. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
4. Trefzer U., Herberth G., Wohlan K., Milling A., Thiemann M., Sherev T., et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 110 (2004) 730-740
5. Gross S., and Walden P. Immunosuppressive mechanisms in human tumors: why we still can not cure cancer. Immunol Lett 116 (2008) 7-14
6. Hodi F.S., Butler M., Oble D.A., Seiden M.V., Haluska F.G., Kruse A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105 (2008) 3005-3010
7. Linnemann T., Tumenjargal S., Gellrich S., Wiesmüller K.H., Kaltoft K., Sterry W., et al. Mimotopes for tumour-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur J Immunol 31 (2001) 156-165
8. Gundlach B.R., Wiesmüller K., Junt T., Kienle S., Jung G., and Walden P. Specificity and degeneracy of minor histocompatibility antigen-specific, MHC-restricted cytotoxic T lymphocytes. J Immunol 156 (1996) 3645-3651
9. Udaka K., Wiesmüller K.H., Kienle S., Jung G., and Walden P. Self-MHC restricted peptides recognized by an allo MHC-responsive CTL clone. J Immunol 157 (1996) 670-678
10. Bredenbeck A., Losch F.O., Sharav T., Eichler-Mertens M., Filter M., Givehchi A., et al. Identification non-canonical melanoma-associated T cell epitopes for cancer immunotherapy. J Immunol 174 (2005) 6716-6724
11. Rubio-Godoy V., Dutoit V., Zhao Y., Simon R., Guillaume P., Houghten R., et al. Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL. J Immunol 169 (2002) 5696-5707
12. Tumenjargal S., Gellrich S., Linnemann T., Muche J.M., Lukowsky A., Audring H., et al. Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope. Eur J Immunol 33 (2003) 3175-3185